TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA

2016 ◽  
Vol 22 (7) ◽  
pp. 822-831 ◽  
Author(s):  
Paritosh Suman ◽  
Chi-Hsiung Wang ◽  
ShabirHusain S. Abadin ◽  
Romy Block ◽  
Vathsala Raghavan ◽  
...  
Keyword(s):  
Overall Survival ◽  
High Risk ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid

Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma

2016 ◽  
Vol 82 (9) ◽  
pp. 807-814 ◽  
Author(s):  
Paritosh Suman ◽  
Chi-Hsiung Wang ◽  
Tricia A. Moo-Young ◽  
Richard A. Prinz ◽  
David J. Winchester
Keyword(s):  
Overall Survival ◽  
Survival Analysis ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Low Risk ◽  
Intermediate Risk ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid ◽  
Risk Patients

There is no consensus regarding the timing of adjuvant radioactive iodine therapy (RAI) therapy in low- and intermediate-risk papillary thyroid carcinoma (PTC). We analyzed the impact of adjuvant RAI on overall survival (OS) in low- and intermediate-risk PTC. The National Cancer Data Base was queried from 2004 to 2011 for pN0M0 PTC patients having near/subtotal or total thyroidectomy and adjuvant RAI. Tumors ≤1 cm with negative margins were low risk while 1.1- to 4-cm tumors with negative margins or ≤1 cm with microscopic margins were termed intermediate risk. RAI in ≤3 months and between 3 and 12 months was termed as early and delayed, respectively. Survival analysis was performed after adjusting for patient and tumor-related variables. There were 7,306 low-risk and 16,609 intermediate-risk patients. Seventeen per cent low-risk and 15 per cent intermediate-risk patients had delayed RAI. Kaplan-Meier analysis did not show a difference in OS for early versus delayed RAI administration in low- (10-year OS 94.5% vs 94%, P = 0.627) or intermediate-risk (10-year OS 95.3% vs 95.9%, P = 0.944) patients. In adjusted survival analysis, RAI timing did not affect OS in all patients (hazard ratios = 0.98, 95% confidence interval = 0.71–1.34, P = 0.887). In conclusion, the timing of postthyroidectomy adjuvant RAI therapy does not affect OS in low- or intermediate-risk PTC.

scholarly journals Management of Papillary Carcinoma of Thyroid with Pulmonary Metastases in Institute of Nuclear Medicine and Allied Sciences, Rajshahi – Two Case Reports

2018 ◽  
Vol 18 (2) ◽  
pp. 179-182
Author(s):  
Md Kabiruzzaman Shah ◽  
Nasrin Begum ◽  
Mosharof Hossain ◽  
Parvez Ahmed ◽  
Sariful Islam Chawdhuary ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Carcinoma ◽  
Radioactive Iodine ◽  
Pulmonary Metastases ◽  
Case Reports ◽  
Young Patients ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid

Papillary thyroid carcinoma with pulmonary metastasis is relatively uncommon which can be treated with radioactive iodine therapy. Here, our experiences with two cases of papillary thyroid carcinoma with pulmonary metastases in young patients are discussed.Bangladesh J. Nuclear Med. 18(2): 179-182, July 2015

Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm

Surgery ◽  
2021 ◽  
Author(s):  
Simon A. Holoubek ◽  
Erin C. MacKinney ◽  
Amna M. Khokar ◽  
Kristine M. Kuchta ◽  
David J. Winchester ◽  
...  
Keyword(s):  
Overall Survival ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Papillary Thyroid
Sign in / Sign up

Export Citation Format

Share Document